Barcelona-Clinic Liver Cancer (BCLC) Staging Classification
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۴
حداقل ۰ • واحد: cm
حداقل ۰
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- 0—
- A—
- B—
- C—
The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include performance status. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.
Clinical Indication
The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification is indicated for bedside clinical practice to support Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: BCLC is the most widely used staging system for HCC as it links stage with treatment recommendations.
BCLC staging is determined by a combination of: 1) Performance Status (ECOG 0-4), 2) Child-Pugh class (A/B/C), 3) Tumor characteristics (size, number, portal invasion, extrahepatic spread)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| performance_status | integer | Yes | ECOG Performance Status (0=Fully active, 1=Restricted in strenuous activity, 2=Ambulatory and capable of self-care, 3=Capable of limited self-care, 4=Completely disabled) |
| child_pugh_class | string | Yes | Child-Pugh classification (A=Well-preserved liver function, B=Moderate liver dysfunction, C=Severe liver damage) |
| tumor_size | float | Yes | Size of the largest tumor in centimeters(cm) |
| number_of_nodules | integer | Yes | Number of tumor nodules |
| portal_invasion | string | Yes | Presence of portal vein invasion (macrovascular invasion) |
| extrahepatic_spread | string | Yes | Presence of extrahepatic spread (metastases) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | 0 | Very Early Stage: Single nodule <2cm, PS 0, Child-Pugh A |
| — | A | Early Stage: Single nodule or up to 3 nodules ≤3cm, PS 0, Child-Pugh A-B |
| — | B | Intermediate Stage: Multinodular, PS 0, Child-Pugh A-B |
| — | C | Advanced Stage: Portal invasion or extrahepatic spread, PS 1-2, Child-Pugh A-B |
| — | D | Terminal Stage: Any tumor burden, PS >2 or Child-Pugh C |
Evidence-Based References (EBM)
- Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018.DOI: 10.1016/j.jhep.2021.11.018
- Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38. doi: 10.1055/s-2007-1007122.DOI: 10.1055/s-2007-1007122
- Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006 Apr;44(4):723-31. doi: 10.1016/j.jhep.2005.12.015.DOI: 10.1016/j.jhep.2005.12.015